MCA
RPRX icon

McGuire Capital Advisors’s Royalty Pharma RPRX Stock Holding History

McGuire Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729 Hold
13
– – ﹤0.01% 800
2026
Q1 		$624 Sell
13
-23
-64% -$1.01K ﹤0.01% 770
2025
Q4 		$1.39K Buy
+36
New +$1.37K ﹤0.01% 740

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

McGuire Capital Advisors's RPRX Position: Q2 2026 in Review

McGuire Capital Advisors held its Royalty Pharma (RPRX) position steady in Q2 2026 at 13 shares worth $729. The position accounts for ﹤0.01% of the portfolio, ranked #800.

McGuire Capital Advisors first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.39K in Q4 2025. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • McGuire Capital Advisors held 13 shares of Royalty Pharma worth $729 as of Q2 2026.
  • McGuire Capital Advisors left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up ﹤0.01% of McGuire Capital Advisors's portfolio in Q2 2026, its #800 holding.
  • McGuire Capital Advisors first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • McGuire Capital Advisors's Royalty Pharma position peaked at $1.39K in Q4 2025.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.